Advertisement

Diabetologia

pp 1–13 | Cite as

Selective deletion of endothelial cell calpain in mice reduces diabetic cardiomyopathy by improving angiogenesis

  • Xiaomei Teng
  • Chen Ji
  • Huiting Zhong
  • Dong Zheng
  • Rui Ni
  • David J. Hill
  • Sidong Xiong
  • Guo-Chang Fan
  • Peter A. Greer
  • Zhenya Shen
  • Tianqing PengEmail author
Article

Abstract

Aims/hypothesis

The role of non-cardiomyocytes in diabetic cardiomyopathy has not been fully addressed. This study investigated whether endothelial cell calpain plays a role in myocardial endothelial injury and microvascular rarefaction in diabetes, thereby contributing to diabetic cardiomyopathy.

Methods

Endothelial cell-specific Capns1-knockout (KO) mice were generated. Conditions mimicking prediabetes and type 1 and type 2 diabetes were induced in these KO mice and their wild-type littermates. Myocardial function and coronary flow reserve were assessed by echocardiography. Histological analyses were performed to determine capillary density, cardiomyocyte size and fibrosis in the heart. Isolated aortas were assayed for neovascularisation. Cultured cardiac microvascular endothelial cells were stimulated with high palmitate. Angiogenesis and apoptosis were analysed.

Results

Endothelial cell-specific deletion of Capns1 disrupted calpain 1 and calpain 2 in endothelial cells, reduced cardiac fibrosis and hypertrophy, and alleviated myocardial dysfunction in mouse models of diabetes without significantly affecting systemic metabolic variables. These protective effects of calpain disruption in endothelial cells were associated with an increase in myocardial capillary density (wild-type vs Capns1-KO 3646.14 ± 423.51 vs 4708.7 ± 417.93 capillary number/high-power field in prediabetes, 2999.36 ± 854.77 vs 4579.22 ± 672.56 capillary number/high-power field in type 2 diabetes and 2364.87 ± 249.57 vs 3014.63 ± 215.46 capillary number/high-power field in type 1 diabetes) and coronary flow reserve. Ex vivo analysis of neovascularisation revealed more endothelial cell sprouts from aortic rings of prediabetic and diabetic Capns1-KO mice compared with their wild-type littermates. In cultured cardiac microvascular endothelial cells, inhibition of calpain improved angiogenesis and prevented apoptosis under metabolic stress. Mechanistically, deletion of Capns1 elevated the protein levels of β-catenin in endothelial cells of Capns1-KO mice and constitutive activity of calpain 2 suppressed β-catenin protein expression in cultured endothelial cells. Upregulation of β-catenin promoted angiogenesis and inhibited apoptosis whereas knockdown of β-catenin offset the protective effects of calpain inhibition in endothelial cells under metabolic stress.

Conclusions/interpretation

These results delineate a primary role of calpain in inducing cardiac endothelial cell injury and impairing neovascularisation via suppression of β-catenin, thereby promoting diabetic cardiomyopathy, and indicate that calpain is a promising therapeutic target to prevent diabetic cardiac complications.

Keywords

β-Catenin Calpain Diabetic cardiomyopathy Endothelial cells Neovascularisation 

Abbreviations

Ad-CAST

Adenoviral vector containing rat calpastatin

Ad-gal

Adenoviral vector containing β-galactosidase

CFR

Coronary flow reserve

CMVEC

Cardiac microvascular endothelial cell

E/A ratio

Ratio of maximal early and late transmitral velocities

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

HFD

High-fat diet

HIF

Hypoxia-inducible factor

KO

Knockout

LV

Left ventricle

MDA

Malondialdehyde

siRNA

Small interfering RNA

STZ

Streptozotocin

VEGF

Vascular endothelial growth factor

Notes

Contribution statement

XT designed the experiments, researched and analysed data, drafted the manuscript and approved the submitted version. CJ researched and interpreted data, drafted the manuscript and approved the submitted version. HZ researched and collected data, drafted the manuscript and approved the submitted version. DZ designed the experiments, researched data, drafted the manuscript and approved the submitted version. RN researched data, drafted the manuscript and approved the submitted version. DJH contributed to the experimental design and discussion, reviewed/edited the manuscript and approved the submitted version. SX contributed to the discussion and the experimental design, reviewed/edited the manuscript, and approved the submitted version. G-CF contributed to the design and discussion, reviewed/revised the manuscript and approved the submitted version. PAG contributed to the generation of endothelial cell Capns1 knockout mice, the design and discussion, reviewed/revised the manuscript and approved the submitted version. ZS contributed to the early conception and design and the discussion, reviewed/revised the manuscript and approved the submitted version. TP designed the study, analysed data, wrote/revised the manuscript and approved/submitted the final version. TP is the guarantor of this work.

Funding

This work was supported by operating grants from the National Natural Science Foundation of China [81470499] and the Canadian Institutes of Health Research [MOP-133657], and by the Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT, IRT1075).

Duality of interest

The authors declare that there is no duality of interest associated with this manuscript.

Supplementary material

125_2019_4828_MOESM1_ESM.pdf (741 kb)
ESM (PDF 740 kb)

References

  1. 1.
    Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442.  https://doi.org/10.1371/journal.pmed.0030442 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr (2004) Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27(3):699–703.  https://doi.org/10.2337/diacare.27.3.699 CrossRefPubMedGoogle Scholar
  3. 3.
    Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223.  https://doi.org/10.1161/CIRCULATIONAHA.106.679597 CrossRefPubMedGoogle Scholar
  4. 4.
    Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83(3):731–801.  https://doi.org/10.1152/physrev.00029.2002 CrossRefPubMedGoogle Scholar
  5. 5.
    Fujitani K, Kambayashi J, Sakon M et al (1997) Identification of mu-, m-calpains and calpastatin and capture of mu-calpain activation in endothelial cells. J Cell Biochem 66(2):197–209.  https://doi.org/10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L CrossRefPubMedGoogle Scholar
  6. 6.
    Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, Greer PA (2006) Conditional disruption of ubiquitous calpains in the mouse. Genesis 44(6):297–303.  https://doi.org/10.1002/dvg.20216 CrossRefPubMedGoogle Scholar
  7. 7.
    Li Y, Ma J, Zhu H et al (2011) Targeted inhibition of calpain reduces myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. Diabetes 60(11):2985–2994.  https://doi.org/10.2337/db10-1333 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li S, Zhang L, Ni R et al (2016) Disruption of calpain reduces lipotoxicity-induced cardiac injury by preventing endoplasmic reticulum stress. Biochim Biophys Acta 1862(11):2023–2033.  https://doi.org/10.1016/j.bbadis.2016.08.005 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ni R, Zheng D, Xiong S et al (2016) Mitochondrial calpain-1 disrupts ATP synthase and induces superoxide generation in type 1 diabetic hearts: a novel mechanism contributing to diabetic cardiomyopathy. Diabetes 65:255–268PubMedGoogle Scholar
  10. 10.
    Aronson D, Edelman ER (2014) Coronary artery disease and diabetes mellitus. Cardiol Clin 32(3):439–455.  https://doi.org/10.1016/j.ccl.2014.04.001 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Beckman JA, Paneni F, Cosentino F, Creager MA (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 34(31):2444–2452.  https://doi.org/10.1093/eurheartj/eht142 CrossRefPubMedGoogle Scholar
  12. 12.
    Hinkel R, Hoewe A, Renner S et al (2017) Diabetes mellitus-induced microvascular destabilization in the myocardium. J Am Coll Cardiol 69(2):131–143.  https://doi.org/10.1016/j.jacc.2016.10.058 CrossRefPubMedGoogle Scholar
  13. 13.
    Muris DM, Houben AJ, Schram MT, Stehouwer CD (2012) Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 32(12):3082–3094.  https://doi.org/10.1161/ATVBAHA.112.300291 CrossRefPubMedGoogle Scholar
  14. 14.
    Sabanayagam C, Lye WK, Klein R et al (2015) Retinal microvascular calibre and risk of diabetes mellitus: a systematic review and participant-level meta-analysis. Diabetologia 58(11):2476–2485.  https://doi.org/10.1007/s00125-015-3717-2 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stalker TJ, Gong Y, Scalia R (2005) The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 54(4):1132–1140.  https://doi.org/10.2337/diabetes.54.4.1132 CrossRefPubMedGoogle Scholar
  16. 16.
    Scalia R, Gong Y, Berzins B, Zhao LJ, Sharma K (2007) Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation: the role of mu-calpain. Diabetes 56(7):1842–1849.  https://doi.org/10.2337/db06-1198 CrossRefPubMedGoogle Scholar
  17. 17.
    Smolock AR, Mishra G, Eguchi K, Eguchi S, Scalia R (2011) Protein kinase C upregulates intercellular adhesion molecule-1 and leukocyte-endothelium interactions in hyperglycemia via activation of endothelial expressed calpain. Arterioscler Thromb Vasc Biol 31(2):289–296.  https://doi.org/10.1161/ATVBAHA.110.217901 CrossRefPubMedGoogle Scholar
  18. 18.
    Chen B, Zhao Q, Ni R et al (2014) Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes. Cardiovasc Diabetol 13(1):88.  https://doi.org/10.1186/1475-2840-13-88 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Randriamboavonjy V, Kyselova A, Elgheznawy A, Zukunft S, Wittig I, Fleming I (2017) Calpain 1 cleaves and inactivates prostacyclin synthase in mesenteric arteries from diabetic mice. Basic Res Cardiol 112(1):10.  https://doi.org/10.1007/s00395-016-0596-8 CrossRefPubMedGoogle Scholar
  20. 20.
    Hinder LM, O’Brien PD, Hayes JM et al (2017) Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech 10(6):717–725.  https://doi.org/10.1242/dmm.028530 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kusakabe T, Tanioka H, Ebihara K et al (2009) Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 52(4):675–683.  https://doi.org/10.1007/s00125-009-1258-2 CrossRefPubMedGoogle Scholar
  22. 22.
    Li Y, Li Y, Feng Q, Arnold M, Peng T (2009) Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 84(1):100–110.  https://doi.org/10.1093/cvr/cvp189 CrossRefPubMedGoogle Scholar
  23. 23.
    Baker M, Robinson SD, Lechertier T et al (2011) Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7(1):89–104.  https://doi.org/10.1038/nprot.2011.435 CrossRefPubMedGoogle Scholar
  24. 24.
    Dror E, Dalmas E, Meier DT et al (2017) Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol 18(3):283–292.  https://doi.org/10.1038/ni.3659 CrossRefPubMedGoogle Scholar
  25. 25.
    Zheng D, Ma J, Yu Y et al (2015) Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice. Diabetologia 58(8):1949–1958.  https://doi.org/10.1007/s00125-015-3622-8 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2(2):329–333.  https://doi.org/10.1038/nprot.2007.30 CrossRefPubMedGoogle Scholar
  27. 27.
    Graesser D, Solowiej A, Bruckner M et al (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 109(3):383–392.  https://doi.org/10.1172/JCI0213595 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Oskarsson G (2004) Coronary flow and flow reserve in children. Acta Paediatr Suppl 93:20–25CrossRefGoogle Scholar
  29. 29.
    Nakagami H, Kaneda Y, Ogihara T, Morishita R (2005) Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 1(1):59–63.  https://doi.org/10.2174/1573399052952550 CrossRefPubMedGoogle Scholar
  30. 30.
    Cohen G, Riahi Y, Alpert E, Gruzman A, Sasson S (2007) The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. Arch Physiol Biochem 113(4-5):259–267.  https://doi.org/10.1080/13813450701783513 CrossRefPubMedGoogle Scholar
  31. 31.
    Heather LC, Clarke K (2011) Metabolism, hypoxia and the diabetic heart. J Mol Cell Cardiol 50(4):598–605.  https://doi.org/10.1016/j.yjmcc.2011.01.007 CrossRefPubMedGoogle Scholar
  32. 32.
    Costa PZ, Soares R (2013) Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci 92(22):1037–1045.  https://doi.org/10.1016/j.lfs.2013.04.001 CrossRefPubMedGoogle Scholar
  33. 33.
    Benetti R, Copetti T, Dell’Orso S et al (2005) The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem 280(23):22070–22080.  https://doi.org/10.1074/jbc.M501810200 CrossRefPubMedGoogle Scholar
  34. 34.
    Shen Y, Zuo S, Wang Y et al (2016) Thromboxane governs the differentiation of adipose-derived stromal cells toward endothelial cells in vitro and in vivo. Circ Res 118(8):1194–1207.  https://doi.org/10.1161/CIRCRESAHA.115.307853 CrossRefPubMedGoogle Scholar
  35. 35.
    Galderisi M (2006) Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 48(8):1548–1551.  https://doi.org/10.1016/j.jacc.2006.07.033 CrossRefPubMedGoogle Scholar
  36. 36.
    Ganote C, Armstrong S (1993) Ischaemia and the myocyte cytoskeleton: review and speculation. Cardiovasc Res 27(8):1387–1403.  https://doi.org/10.1093/cvr/27.8.1387 CrossRefPubMedGoogle Scholar
  37. 37.
    Moe GW, Marin-Garcia J (2016) Role of cell death in the progression of heart failure. Heart Fail Rev 21(2):157–167.  https://doi.org/10.1007/s10741-016-9532-0 CrossRefPubMedGoogle Scholar
  38. 38.
    Crea F, Camici PG, Bairey Merz CN (2014) Coronary microvascular dysfunction: an update. Eur Heart J 35(17):1101–1111.  https://doi.org/10.1093/eurheartj/eht513 CrossRefPubMedGoogle Scholar
  39. 39.
    Stalker TJ, Skvarka CB, Scalia R (2003) A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J 17(11):1511–1513.  https://doi.org/10.1096/fj.02-1213fje CrossRefPubMedGoogle Scholar
  40. 40.
    Bodnar RJ, Rodgers ME, Chen WC, Wells A (2013) Pericyte regulation of vascular remodeling through the CXC receptor 3. Arterioscler Thromb Vasc Biol 33(12):2818–2829.  https://doi.org/10.1161/ATVBAHA.113.302012 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Yildirim C, Favre J, Weijers EM et al (2015) IFN-β affects the angiogenic potential of circulating angiogenic cells by activating calpain 1. Am J Physiol Heart Circ Physiol 309(10):H1667–H1678.  https://doi.org/10.1152/ajpheart.00810.2014 CrossRefPubMedGoogle Scholar
  42. 42.
    Su Y, Cui Z, Li Z, Block ER (2006) Calpain-2 regulation of VEGF-mediated angiogenesis. FASEB J 20(9):1443–1451.  https://doi.org/10.1096/fj.05-5354com CrossRefPubMedGoogle Scholar
  43. 43.
    Miyazaki T, Honda K, Ohata H (2010) m-Calpain antagonizes RhoA overactivation and endothelial barrier dysfunction under disturbed shear conditions. Cardiovasc Res 85(3):530–541.  https://doi.org/10.1093/cvr/cvp311 CrossRefPubMedGoogle Scholar
  44. 44.
    Zhang Y, Li Q, Youn JY, Cai H (2017) Protein phosphotyrosine phosphatase 1B (PTP1B) in calpain-dependent feedback regulation of vascular endothelial growth factor receptor (VEGFR2) in endothelial cells: implications in VEGF-dependent angiogenesis and diabetic wound healing. J Biol Chem 292(2):407–416.  https://doi.org/10.1074/jbc.M116.766832 CrossRefPubMedGoogle Scholar
  45. 45.
    Li G, Iyengar R (2002) Calpain as an effector of the Gq signaling pathway for inhibition of Wnt/beta -catenin-regulated cell proliferation. Proc Natl Acad Sci U S A 99(20):13254–13259.  https://doi.org/10.1073/pnas.202355799 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Rios-Doria J, Kuefer R, Ethier SP, Day ML (2004) Cleavage of beta-catenin by calpain in prostate and mammary tumor cells. Cancer Res 64(20):7237–7240.  https://doi.org/10.1158/0008-5472.CAN-04-1048 CrossRefPubMedGoogle Scholar
  47. 47.
    Xi XH, Wang Y, Li J, Wang FW, Tian GH, Yin MS, Mu YL, Chong ZZ (2015) Activation of Wnt/beta-catenin/GSK3beta signaling during the development of diabetic cardiomyopathy. Cardiovasc Pathol 24(3):179–186.  https://doi.org/10.1016/j.carpath.2014.12.002 CrossRefPubMedGoogle Scholar
  48. 48.
    Ying Y, Zhu H, Liang Z, Ma X, Li S (2015) GLP1 protects cardiomyocytes from palmitate-induced apoptosis via Akt/GSK3b/b-catenin pathway. J Mol Endocrinol 55(3):245–262.  https://doi.org/10.1530/JME-15-0155 CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Huang CJ, Gurlo T, Haataja L et al (2010) Calcium-activated calpain-2 is a mediator of beta cell dysfunction and apoptosis in type 2 diabetes. J Biol Chem 285(1):339–348.  https://doi.org/10.1074/jbc.M109.024190 CrossRefPubMedGoogle Scholar
  50. 50.
    Shanab AY, Nakazawa T, Ryu M et al (2012) Metabolic stress response implicated in diabetic retinopathy: the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiol Dis 48(3):556–567.  https://doi.org/10.1016/j.nbd.2012.07.025 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xiaomei Teng
    • 1
    • 2
    • 3
    • 4
    • 5
  • Chen Ji
    • 1
  • Huiting Zhong
    • 1
  • Dong Zheng
    • 4
    • 5
  • Rui Ni
    • 4
    • 5
  • David J. Hill
    • 4
    • 6
    • 7
  • Sidong Xiong
    • 1
  • Guo-Chang Fan
    • 8
  • Peter A. Greer
    • 9
    • 10
  • Zhenya Shen
    • 2
    • 3
  • Tianqing Peng
    • 1
    • 4
    • 5
    • 6
    Email author
  1. 1.Institutes of Biology and Medical SciencesSoochow UniversitySuzhouChina
  2. 2.Department of Cardiovascular Surgery of the First Affiliated HospitalSoochow UniversitySuzhouChina
  3. 3.Institute for Cardiovascular ScienceSoochow UniversitySuzhouChina
  4. 4.Critical Illness ResearchLawson Health Research InstituteLondonCanada
  5. 5.Department of Pathology and Laboratory MedicineWestern UniversityLondonCanada
  6. 6.Department of MedicineWestern UniversityLondonCanada
  7. 7.Department of Physiology and PharmacologyWestern UniversityLondonCanada
  8. 8.Department of Pharmacology and Systems PhysiologyUniversity of Cincinnati College of MedicineCincinnatiUSA
  9. 9.Division of Cancer Biology and Genetics, Queen’s University Cancer Research InstituteQueen’s UniversityKingstonCanada
  10. 10.Department of Pathology and Molecular MedicineQueen’s UniversityKingstonCanada

Personalised recommendations